VGA039
- Generic Name
- VGA039
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
VGA039 is an IgG4 monoclonal antibody directed against protein S.
- Associated Conditions
- -
- Associated Therapies
- -
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039, a Novel Antibody Therapy for von Willebrand Disease
Vega Therapeutics received FDA orphan drug designation for VGA039, a novel antibody therapy for von Willebrand disease (VWD), targeting Protein S to enhance clot formation. VGA039, in Phase 1 trials, aims to reduce treatment burden and improve patient outcomes in VWD and other bleeding disorders.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath